Taiwan · Delayed Price · Currency is TWD Medigen Vaccine Biologics Company Description
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan.
It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses.
The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19.
Medigen Vaccine Biologics Corporation was incorporated in 2012 and is headquartered in Zhubei City, Taiwan.
Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.
| Country | Taiwan |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 103 |
| CEO | Leo Lee |
Contact Details
Address: No. 68, Shengyi 3rd Road Zhubei City, 30261 Taiwan | |
| Phone | 886 3 668 4866 |
| Website | medigenvac.com |
Stock Details
| Ticker Symbol | 6547 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006547003 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Leo Lee | Chief Executive Officer and Executive Vice President |
| Yu-Ping Yang | Chief Financial Officer |
| Jia-En Liang | Deputy General Manager of International and Public Affairs |
| Shih-Shen Lee | Executive Vice President of Operations Business Unit |